Dr. Tiffany H. Svahn
Claim this profileJohn Muir Medical Center-Walnut Creek
Studies Breast Cancer
Studies Cancer
2 reported clinical trials
5 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
ER negative
2Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Tiffany H. Svahn is currently running
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Tiffany H. Svahn
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tiffany H. Svahn has experience with
- Trastuzumab Emtansine
- Tucatinib
- Paclitaxel
- Pertuzumab
- Trastuzumab
Breakdown of trials Tiffany H. Svahn has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tiffany H. Svahn specialize in?
Tiffany H. Svahn focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Tiffany H. Svahn currently recruiting for clinical trials?
Yes, Tiffany H. Svahn is currently recruiting for 2 clinical trials in Walnut Creek California. If you're interested in participating, you should apply.
Are there any treatments that Tiffany H. Svahn has studied deeply?
Yes, Tiffany H. Svahn has studied treatments such as Trastuzumab Emtansine, Tucatinib, Paclitaxel.
What is the best way to schedule an appointment with Tiffany H. Svahn?
Apply for one of the trials that Tiffany H. Svahn is conducting.
What is the office address of Tiffany H. Svahn?
The office of Tiffany H. Svahn is located at: John Muir Medical Center-Walnut Creek, Walnut Creek, California 94598 United States. This is the address for their practice at the John Muir Medical Center-Walnut Creek.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.